Eli Lilly and Co (LLY) : Greenwood Capital Associates reduced its stake in Eli Lilly and Co by 1.22% during the most recent quarter end. The investment management company now holds a total of 47,558 shares of Eli Lilly and Co which is valued at $3,815,103 after selling 588 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Eli Lilly and Co makes up approximately 1.13% of Greenwood Capital Associates’s portfolio.
Other Hedge Funds, Including , Bergankdv Wealth Management boosted its stake in LLY in the latest quarter, The investment management firm added 495 additional shares and now holds a total of 4,501 shares of Eli Lilly and Co which is valued at $361,070. Eli Lilly and Co makes up approx 0.15% of Bergankdv Wealth Management’s portfolio.Burney Co reduced its stake in LLY by selling 2,496 shares or 1.71% in the most recent quarter. The Hedge Fund company now holds 143,054 shares of LLY which is valued at $11,475,792. Eli Lilly and Co makes up approx 0.79% of Burney Co’s portfolio.Waverton Investment Management Ltd reduced its stake in LLY by selling 55 shares or 0.22% in the most recent quarter. The Hedge Fund company now holds 25,251 shares of LLY which is valued at $2,093,055. Eli Lilly and Co makes up approx 0.15% of Waverton Investment Management Ltd’s portfolio.Louisiana State Employees Retirement System reduced its stake in LLY by selling 1,400 shares or 2.15% in the most recent quarter. The Hedge Fund company now holds 63,700 shares of LLY which is valued at $5,312,580. Eli Lilly and Co makes up approx 0.27% of Louisiana State Employees Retirement System’s portfolio.
Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.